These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 17875482

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ, Soon-Shiong P, Desai N.
    Adv Drug Deliv Rev; 2008 May 22; 60(8):876-85. PubMed ID: 18423779
    [Abstract] [Full Text] [Related]

  • 3. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
    Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1317-24. PubMed ID: 16489089
    [Abstract] [Full Text] [Related]

  • 4. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
    Stinchcombe TE.
    Nanomedicine (Lond); 2007 Aug 15; 2(4):415-23. PubMed ID: 17716129
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
    Lluch A, Alvarez I, Muñoz M, Seguí MÁ, Tusquets I, García-Estévez L.
    Crit Rev Oncol Hematol; 2014 Jan 15; 89(1):62-72. PubMed ID: 24071503
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J, Chua SL.
    Breast; 2011 Oct 15; 20(5):394-406. PubMed ID: 21839635
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F, Borgonovo K, Barni S.
    Expert Opin Pharmacother; 2010 Jun 15; 11(8):1413-32. PubMed ID: 20446855
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
    Henderson IC, Bhatia V.
    Expert Rev Anticancer Ther; 2007 Jul 15; 7(7):919-43. PubMed ID: 17627452
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations.
    Li Y, Chen N, Palmisano M, Zhou S.
    Mol Pharm; 2015 Apr 06; 12(4):1308-17. PubMed ID: 25714793
    [Abstract] [Full Text] [Related]

  • 18. Paclitaxel nanoparticles for the potential treatment of brain tumors.
    Koziara JM, Lockman PR, Allen DD, Mumper RJ.
    J Control Release; 2004 Sep 30; 99(2):259-69. PubMed ID: 15380635
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy evaluation of albumin-bound paclitaxel.
    Cecco S, Aliberti M, Baldo P, Giacomin E, Leone R.
    Expert Opin Drug Saf; 2014 Apr 30; 13(4):511-20. PubMed ID: 24559090
    [Abstract] [Full Text] [Related]

  • 20. Albumin-bound Paclitaxel: in metastatic breast cancer.
    Robinson DM, Keating GM.
    Drugs; 2006 Apr 30; 66(7):941-8. PubMed ID: 16740010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.